Plasmonic gold nanoagents for cancer imaging and therapy

Fu, Qinrui; Zhang, Xuan; Song, Jibin; Yang, Huanghao

doi:10.1002/viw.20200149

Cited by 33 publications

(23 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Researchers should focus on utilizing contrast agents as an “all-in-one” nanotheranostic platform to allow real-time diagnosis and synchronous treatment. For example, AuNPs, with controllable size, easy surface modification, perfect radiosensitization capability, tunable optical properties, and high X-ray attenuation, can simultaneously realize multimodal (CT, MR, PA) image-guided synergistic treatment (RT, PTT) 191 .…”

Section: Discussionmentioning

confidence: 99%

Nanomaterial-based CT contrast agents and their applications in image-guided therapy

Jiang¹,

Zhang²,

Li³

et al. 2023

Theranostics

Self Cite

View full text Add to dashboard Cite

Computed tomography (CT), a diagnostic tool with clinical application, comprehensive coverage, and low cost, is used in hospitals worldwide. However, CT imaging fails to distinguish soft tissues from normal organs and tumors because their mass attenuation coefficients are similar. Various CT contrast agents have been developed in recent years to improve the sensitivity and contrast of imaging. Here, we review the progress of nanomaterial-based CT contrast agents and their applications in image-guided therapy. The CT contrast agents are classified according to their components; gold (Au)-based, bismuth (Bi)-based, lanthanide (Ln)-based, and transition metal (TM)-based nanomaterials are discussed. CT image-guided therapy of diseases, including photothermal therapy (PPT), photodynamic therapy (PDT), chemotherapy, radiotherapy (RT), gas therapy, sonodynamic therapy (SDT), immunotherapy, starvation therapy, gene therapy (GT), and microwave thermal therapy (MWTT), are reviewed. Finally, the perspectives on the CT contrast agents and their biomedical applications are discussed.

show abstract

Section: Discussionmentioning

confidence: 99%

Nanomaterial-based CT contrast agents and their applications in image-guided therapy

Jiang¹,

Zhang²,

Li³

et al. 2023

Theranostics

Self Cite

View full text Add to dashboard Cite

show abstract

“…On the basis of the above characteristics, we design and fabricate the poly(vinylpyrrolidone) coated Ta NPs (Ta@PVP NPs) and explore them as radiosensitizers and photothermal agents for inhibiting the growth of both primary tumor and metastatic SLNs (Scheme ). First, for primary tumor treatment, Ta@PVP NPs with a high atomic number (Z = 73) and density (16.6 g/cm 3 ) process strong X-ray attenuation ability and better radiosensitization effects for local tumor inhibition . Second, for metastatic SLNs treatment, we find that Ta@PVP NPs with an appropriate size could efficiently target and migrate to nearby SLNs from the primary tumor.…”

Section: Introductionmentioning

confidence: 86%

Biocompatible Tantalum Nanoparticles as Radiosensitizers for Enhancing Therapy Efficacy in Primary Tumor and Metastatic Sentinel Lymph Nodes

Zhao

Wang

et al. 2022

ACS Nano

View full text Add to dashboard Cite

Metastasis of breast carcinoma is commonly realized through lymphatic circulation, which seriously threatens the lives of breast cancer patients. Therefore, efficient therapy for both primary tumor and metastatic sentinel lymph nodes (SLNs) is highly desired to inhibit cancer growth and metastasis. During breast cancer treatment, radiotherapy (RT) is a common clinical method. However, the efficacy of RT is decreased by the radioresistance to a hypoxic microenvironment and inevitable side effects for healthy issues at high radiation doses. Considering the above-mentioned, we provide high biocompatible poly(vinylpyrrolidone) coated Ta nanoparticles (Ta@PVP NPs) for photothermal therapy (PTT) assisted RT for primary tumor and metastatic SLNs. On the one hand, for primary tumor treatment, Ta@PVP NPs with a high X-ray mass attenuation coefficient (4.30 cm 2 /kg at 100 keV) can deposit high radiation doses within tumors. On the other hand, for metastatic SLNs treatment, the effective delivery of Ta@ PVP NPs from the primary tumor into SLNs is monitored by computed tomography and photoacoustic imaging, which greatly benefit the prognosis and treatment for metastatic SLNs. Moreover, Ta@PVP NPs-mediated PTT could enhance the RT effect, and immunogenic cell death caused by RT/PTT could induce an immune response to improve the therapeutic effect of metastatic SLNs. This study not only explores the potential of Ta@PVP NPs as effective radiosensitizers and photothermal agents for combined RT and PTT but also offers an efficient strategy to cure both primary tumor and metastatic SLNs in breast carcinoma.

show abstract

“…The past few decades have witnessed the rapid development of nanotechnology, especially in nanodrug delivery, including improved drug solubility, prolonged circulation time, preferential accumulation of drug at lesion area and reduced systemic side effects. [33][34][35] Copper-based nanomaterials represent a novel class of cuproptosis inducers, which can achieve active targeting by surface modifications and passively accumulate to tumor site via enhanced permeability and retention (EPR) effect. 36,37 The excessive copper ion binding to DLAT in tumor cells causes aggregation of lipoacylated DLAT, and induces destabilization of Fe-S cluster proteins, which ultimately leads to cuproptosis of tumor cells, thus exert therapeutic effect.…”

Section: Introductionmentioning

confidence: 99%

Cell death mediated by nanotechnology via the cuproptosis pathway: a novel horizon for cancer therapy

Wei

2023

Preprint

View full text Add to dashboard Cite

Cuproptosis, the current form of regulated cell death characterized by copper overload, oligomerization of lipoacylated proteins, and loss of the Fe-S cluster proteins, has been proposed to function closely with human diseases including cancer. Since the first identification in 2022, a wide range of strategies have been developed to induce cuproptosis for cancer therapy, such as small-molecule drugs and nanomaterials. Although many reviews related to cuproptosis have been reported, they remain at a basic mechanism level and a summary covering recent progress in the field of nanotechnologies in cuproptosis-based cancer therapy has not yet been presented. Therefore, it is time to fill the gap and shed light on future directions for the application of this promising tool to fight against cancer. In this minireview, we first expounded the mechanism of action of cuproptosis and emphasized the feasibility of triggering cuproptosis for cancer therapy. The recent progress of cancer treatments based on nanoparticle-induced cuproptosis was then described. Finally, the challenges and future development directions of the emerging field of cuproptosis were also discussed.

show abstract

Plasmonic gold nanoagents for cancer imaging and therapy

Cited by 33 publications

References 101 publications

Nanomaterial-based CT contrast agents and their applications in image-guided therapy

Nanomaterial-based CT contrast agents and their applications in image-guided therapy

Biocompatible Tantalum Nanoparticles as Radiosensitizers for Enhancing Therapy Efficacy in Primary Tumor and Metastatic Sentinel Lymph Nodes

Cell death mediated by nanotechnology via the cuproptosis pathway: a novel horizon for cancer therapy

Contact Info

Product

Resources

About